Benefits of the Topical JAK Inhibitor Delgocitinib in a Patient With Pediatric Localized Scleroderma

Mayuko Yamamoto; Kimiko Nakajima; Mayuko Matsuda; Aya Takahashi; Kozo Nakai

doi:10.1111/pde.15844

Benefits of the Topical JAK Inhibitor Delgocitinib in a Patient With Pediatric Localized Scleroderma

Pediatr Dermatol. 2024 Dec 10. doi: 10.1111/pde.15844. Online ahead of print.

Authors

Mayuko Yamamoto¹, Kimiko Nakajima¹, Mayuko Matsuda², Aya Takahashi¹, Kozo Nakai¹

Affiliations

¹ Department of Dermatology, Kochi Medical School, Kochi University, Kochi, Japan.
² Department of Dermatology, Graduate School of Medical, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan.

PMID: 39659052
DOI: 10.1111/pde.15844

Abstract

This is the first report of pediatric linear scleroderma successfully treated with the topical Janus kinase (JAK) inhibitor delgocitinib. JAK inhibitors targeting the JAK/STAT pathway have been used to treat various immune-mediated diseases. In both in vitro and in vivo, JAK inhibitors also block the transforming growth factor (TGF)-β-mediated effects that contribute to skin sclerosis. In the present case, the histological findings of inflammation and fibrosis were considered as conditions that would benefit from the anti-inflammatory and antifibrotic effects of the JAK inhibitor, delgocitinib.

Keywords: delgocitinib; linear scleroderma; pediatric; topical JAK inhibitor.

Publication types

Case Reports